CaseStudies

1. Mammalian Expression 5/28/2026

   See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges. 

2. Deepening Digitalization In Drug Discovery At PTC Therapeutics 5/28/2026

   Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.

3. Accelerating Structure Verification Across Novartis 5/28/2026

   Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.

4. How GSK Are Revolutionizing HTE 5/28/2026

   High-throughput chemistry delivers speed and efficiency, but only with the right digital backbone. See how integrated automation and analytics help chemists extract more value from every plate.

5. Simplify And Streamline Method Development With In Silico Modeling 5/19/2026

   Automated screening paired with in silico modeling can cut method development time while improving robustness. See how combining experimentation and simulation enables faster decision‑making.

6. LYO Cycle Development Ensures Success For Oncology Drug Scale-Up 5/14/2026

   An optimized lyophilization cycle removes excess moisture during scale‑up by adjusting drying for larger equipment, improving stability, maintaining efficiency, and supporting clinical validation.

7. Integrated Drug Discovery: Hit To PCC In 16 Months 5/8/2026

   Accelerate your drug discovery program with integrated, cross-functional expertise that advances promising candidates from hit identification to preclinical development with speed and efficiency.

8. How A Global Biosimilars Company Cut Manual Data Errors By 50% 5/8/2026

   Learn how a global biopharmaceutical leader halved transcription errors and integrated over 350 instruments to accelerate the development of high-quality, clinically proven biosimilars.

9. From 51% Yield To 87% With Targeted Impurity Removal 5/7/2026

   Targeted impurity identification and purification redesign dramatically improved yield, reduced process complexity, and enabled reliable API supply for Phase II clinical development.

10. Overcoming Product Instability And Improving Yield 5/7/2026

    Early identification of hidden product instability enabled rapid process adjustments, improving yield and keeping a preclinical toxicology program on track despite challenging reaction conditions.